Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report

Crizotinib, a small molecular tyrosine kinase inhibitor, manifests dramatic responses in patients with non-small cell lung cancer with echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) rearrangements. ALK gene point mutation is the primary mechanism of acquired c...

Description complète

Détails bibliographiques

Auteurs principaux:	Ling Zhang, Yunxia Li, Shaohong Zhang, Chen Gao, Keke Nie, Youxin Ji
Format:	Artigo
Langue:	Inglês
Publié:	China Anti-Cancer Association 2018-06-01
Collection:	Cancer Biology & Medicine
Sujets:	Non-small cell lung cancer EML4-ALK target therapy crizotinib
Accès en ligne:	http://www.cancerbiomed.org/index.php/cocr/article/view/1133
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!